Get the Stockscreener App
12.51
10.64%
-1.49
Gh Research Plc stock is traded at $12.51, with a volume of 375.53K.
It is down -10.64% in the last 24 hours and up +39.15% over the past month.
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. The company is focused on developing novel and proprietary Mebufotenin 5-Methoxy-N, N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment-Resistant Depression, or TRD.
See More
Previous Close:
$14.00
Open:
$14.3
24h Volume:
375.53K
Relative Volume:
0.97
Market Cap:
$775.97M
Revenue:
-
Net Income/Loss:
$-41.43M
P/E Ratio:
-15.84
EPS:
-0.79
Net Cash Flow:
$-39.97M
1W Performance:
-12.58%
1M Performance:
+39.15%
6M Performance:
+12.80%
1Y Performance:
+62.26%
1-Day Range:
$12.41
$14.36
1-Week Range:
$12.41
$14.64
52-Week Range:
$6.00
$20.50
Gh Research Plc Stock (GHRS) Company Profile
Compare GHRS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GHRS
Gh Research Plc
|
12.51 | 775.97M | 0 | -41.43M | -39.97M | -0.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Gh Research Plc Stock (GHRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-13-25 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-16-22 | Initiated | H.C. Wainwright | Buy |
| Jun-16-22 | Initiated | ROTH Capital | Buy |
Gh Research Plc Stock (GHRS) Latest News
Small-Cap Stocks Surge: GH Research, Society Pass and Reborn Coffee Lead Monday Gainers - HPBL
GHRS Stock Rallies 55% in a Week: Here's What You Should Know - MSN
Cantor Fitzgerald Forecasts GH Research FY2024 Earnings - Defense World
GH Research (NASDAQ:GHRS) Earns Overweight Rating from Analysts at Cantor Fitzgerald - MarketBeat
Cantor Fitzgerald Initiates Coverage of GH Research (GHRS) with Overweight Recommendation - MSN
Cantor Fitzgerald sets GH Research stock Overweight, $14 target By Investing.com - Investing.com Australia
Cantor Fitzgerald sets GH Research stock Overweight, $14 target - MSN
GH Research initiated with an Overweight at Cantor Fitzgerald - TipRanks
Cantor Fitzgerald Initiates GH Research at Overweight -February 13, 2025 at 07:35 am EST - Marketscreener.com
GH Research - The Pharma Letter
These 5 Health Care Stocks Saw The Sharpest Retail Interest Jump Last Week - NewsBreak
GH Research (NASDAQ:GHRS) Shares Gap UpStill a Buy? - MarketBeat
GH Research PLC's (NASDAQ:GHRS) Top Key Executive Florian Schonharting is the most upbeat insider, and their holdings increased by 31% last week - Yahoo Finance
GH Research (NASDAQ:GHRS) Reaches New 12-Month HighWhat's Next? - MarketBeat
GH Research (NASDAQ:GHRS) Stock Price Down 7.6%Here's What Happened - MarketBeat
GH Research PLC (NASDAQ: GHRS) Up 56.77% From 52-Week Low; YTD Jumps 98.21% – Here’s What To Do Now - Marketing Sentinel
GH Research (NASDAQ:GHRS) Shares Gap DownHere's What Happened - MarketBeat
GH Research (NASDAQ:GHRS) Hits New 1-Year HighShould You Buy? - MarketBeat
GH Research PLC Raises $139.8 Million Through Share Offering - TipRanks
Taking on analysts’ expectations and winning: GH Research PLC (GHRS) - SETE News
Financial Metrics Unveiled: GH Research PLC (GHRS)’s Key Ratios in the Spotlight - The Dwinnex
Where are the Opportunities in (GHRS) - Stock Traders Daily
H.C. Wainwright maintains buy on GH Research stock, $40 target - MSN
GH Research PLC (GHRS) stock: A year of ups and downs - US Post News
GH Research Secures $150 Million in Public Offering - TipRanks
GH Research Announces Pricing of $150 Million Public Offering By Investing.com - Investing.com Nigeria
ForexTV | Small Business Resources - ForexTV.com
GH Research Prices Public Offering Of 10 Mln Shares At $15.00/shr - Nasdaq
Major Biotech Stock Offering: GH Research Secures $150M War Chest Through Share Sale - StockTitan
GH Research Announces Pricing of $150 Million Public Offering - Yahoo Finance
GH Research PLC [GHRS] is 157.00% higher this YTD. Is it still time to buy? - The DBT News
H.C. Wainwright maintains buy on GH Research stock, $40 target By Investing.com - Investing.com Australia
Why GH Research PLC (GHRS) Is Skyrocketing So Far In 2025 - MSN
GH Research launches $150 million offering - Green Market Report
Shares Soar as GH Research Unveils Promising Drug Trial - Value the Markets
GH Research Announces Proposed Public Offering - The Manila Times
Why These 15 Healthcare Stocks Are Skyrocketing So Far In 2025 - Insider Monkey
Healthcare's Hidden Gem: Why GH Research PLC Stock is Surging in 2025! - Jomfruland.net
GH Research stock target raised to $42 at Rodman & Renshaw - Investing.com India
GH Research Announces Primary Endpoint Met in Phase 2b - GlobeNewswire
GH Research stock target raised to $42 at Rodman & Renshaw By Investing.com - Investing.com South Africa
Gh Research Plc Stock (GHRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):